Zoek in het archief
 
terug

Check the original
News breaking: 2017-07-10

Data van fase III-onderzoek naar bispecifiek antilichaam emicizumab van Chugai bij patiënten met hemofilie A en remmers gepubliceerd in The New England Journal of Medicine Online

15:46 uur 10-07-2017

Data van fase III-onderzoek naar bispecifiek antilichaam emicizumab van Chugai bij patiënten met hemofilie A en remmers gepubliceerd in The New England Journal of Medicine Online

TOKYO–(BUSINESS WIRE)– Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) heeft vandaag bekendgemaakt dat data uit het onderzoek HAVEN 1 (NCT02622321) zijn gepubliceerd in de online versie van The New England Journal of Medicine (NEJM). Het internationale fase III-onderzoek draaide om de bispecifieke antistof emicizumab bij volwassenen en adolescenten met hemofilie A met remmers. De resultaten van HAVEN 1 en de tussentijdse analyse van het onderzoek HAVEN 2 ((NCT02795767), een internationaal fase III-onderzoek naar emicizumab bij pediatrische patiënten met hemofilie A, zijn vandaag gepresenteerd op het 26e congres van de International Society on Thrombosis and Haemostasis (ISTH) in Berlijn.

Chugai’s Bispecific Antibody “Emicizumab” Global Phase III Data in Patients with Haemophilia A with Inhibitors Published in The New England Journal of Medicine Online

TOKYO–(BUSINESS WIRE)– Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the data from HAVEN 1 study (NCT02622321) was published in the online version of The New England Journal of Medicine (NEJM). This global phase III study examined Chugai’s bispecific antibody emicizumab in adults and adolescents 12 years of age or older with haemophilia A with inhibitors. Results of HAVEN 1 study and the interim analysis of HAVEN 2 study (NCT02795767), a global phase III study of emicizumab in paediatric patients with haemophilia A with inhibitors, are presented today at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting in Berlin.

“HAVEN 1 study is the first global phase III study for emicizumab. This important data provides the body of evidence for the upcoming new drug application,” said Chugai’s President & COO, Tatsuro Kosaka. “The interim analysis of HAVEN 2 study showed that emicizumab offers benefit for children as well. Chugai is committed to provide a new treatment option as soon as possible for the disease which may severely affect patients’ life.” Chugai is currently preparing to file the new drug application in Japan for emicizumab based on the data of HAVEN 1 study and the interim analysis of HAVEN 2 study. These data have been filed with the US Food and Drug Administration (FDA) and the European Medicines Agency by Roche. Emicizumab was designated as a Breakthrough Therapy by the FDA for the prophylactic treatment of people who are 12 years or older with haemophilia A with factor VIII inhibitor in September 2015.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170710005574/en/

Contacts

For Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group, Corporate Communications Dept.,

Koki Harada

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

***

For US media

Chugai Pharma USA Inc.

Casey Astringer

Tel: +1-908-516-1350

E-mail: pr@chugai-pharm.com

***

For European media

Chugai Pharma France SAS

Nathalie Leroy

Tel: +33-1-56-37-05-21

E-mail: pr@chugai.eu

***

For Taiwanese media

Chugai Pharma Taiwan Ltd.

Susan Chou, Osamu Kagawa

Tel: +886-2-2715-2000

E-mail: pr@chugai.com.tw

***

For Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group, Corporate Communications Dept.,

Toshiya Sasai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.